Spark Therapeutics offers a glimpse of efficacy in first two hemophilia A gene therapy patients – Endpoints News
Endpoints News |
Spark Therapeutics offers a glimpse of efficacy in first two hemophilia A gene therapy patients
Endpoints News Noted Jefferies' Michael Yee recently: “First data from Phase I/II of Hemophilia A gene therapy SPK-8011 in July/Aug could establish early proof-of-concept and be a (+) catalyst. Given small no. of pts to start, key is demonstrating potential to get to … Spark Therapeutics Inc (ONCE): Showing Signs Of Making It Big |
